他克莫司/甲氨蝶呤与他克莫司/减量甲氨蝶呤/霉酚酸酯预防移植物抗宿主病的比较
该随机试验比较他克莫司/甲氨蝶呤(full-MTX)与他克莫司/减量甲氨蝶呤/霉酚酸酯(mini-MTX/MMF)在异基因造血干细胞移植后预防移植物抗宿主病的效果。96例患者随机分组,mini-MTX/MMF组2-4级急性GVHD无显著差异,但3-4级急性GVHD发生率较高(13% vs 4%;P = .07),黏膜炎和植入更快,肾毒性和呼吸衰竭更少。1年复发率和总生存无差异,非复发死亡较低但未达统计学显著(11% vs 22%;P = .06)。
要点
- mini-MTX/MMF组2-4级急性GVHD与full-MTX组无显著差异(28% vs 27%;P = .41)。
- mini-MTX/MMF组3-4级急性GVHD发生率较高(13% vs 4%;P = .07)。
- mini-MTX/MMF组3或4级黏膜炎更低、植入更快,肾毒性和呼吸衰竭更少。
核心结论
- 与full-MTX相比,mini-MTX/MMF在2-4级急性GVHD方面无差异,且毒性特征更有利。
- 较高的严重急性GVHD发生率需要进一步研究以优化该方案。
研究设计与样本
- 随机试验,比较他克莫司/甲氨蝶呤(full-MTX)与他克莫司/减量甲氨蝶呤/霉酚酸酯(mini-MTX/MMF)预防GVHD。
- 纳入接受首次清髓性造血干细胞移植、使用8/8 HLA相合供者的患者。
- 96例患者随机分配至full-MTX组(N = 49)或mini-MTX组(N = 47);86%使用骨髓移植物。
- 主要终点为急性GVHD、黏膜炎和植入发生率;次要终点包括慢性GVHD、器官毒性、感染、复发、非复发死亡和总生存。
- 试验注册于www.clinicaltrials.gov,编号#NCT01951885。
主要发现
- 2-4级急性GVHD发生率:mini-MTX/MMF组28% vs full-MTX组27%(P = .41),无显著差异。
- 3-4级急性GVHD发生率:mini-MTX/MMF组13% vs full-MTX组4%(P = .07)。
- mini-MTX/MMF组3或4级黏膜炎更低,植入更快。
- 1年中重度慢性GVHD和感染无差异。
- mini-MTX/MMF组肾毒性和呼吸衰竭更少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出较高的严重急性GVHD发生率需要进一步研究以优化该方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tacrolimus (Tac)/methotrexate (MTX) is standard graft-versus-host disease (GVHD) prophylaxis; however, is associated with several toxicities. Tac, reduced-dose MTX (mini-MTX), and mycophenolate mofetil (MMF) have been used but never compared with standard MTX. We performed a randomized trial comparing Tac/MTX (full-MTX) with Tac/mini-MTX/MMF (mini-MTX/MMF) for GVHD prevention after allogeneic hematopoietic cell transplantation (HCT). Patients (pts) receiving first myeloablative HCT using an 8/8 HLA-matched donor were eligible. Primary end points were incidence of acute GVHD (aGVHD), mucositis, and engraftment. Secondary end points included chronic GVHD (cGVHD), organ toxicity, infection, relapse, nonrelapse mortality (NRM), and overall survival (OS). Ninety-six pts were randomly assigned to full-MTX (N = 49) or mini-MTX (N = 47). The majority (86%) used bone marrow grafts. There was no significant difference in grade 2-4 aGVHD (28% mini-MTX/MMF vs 27% full-MTX; P = .41); however higher incidence of grade 3-4 aGVHD (13% vs 4%; P = .07) with mini-MTX/MMF. Pts receiving mini-MTX/MMF had lower grade 3 or 4 mucositis and faster engraftment. There were no differences in moderate-to-severe cGVHD at 1 year or infections. Pts receiving mini-MTX/MMF experienced less nephrotoxicity and respiratory failure. There was no difference in the 1-year relapse (19% vs 21%; P = .89) and OS (72% vs 71%; P = .08), and mini-MTX/MMF was associated with lower but nonsignificant NRM (11% vs 22%; P = .06). Compared with full-MTX, mini-MTX/MMF was associated with no difference in grade 2-4 aGVHD and a more favorable toxicity profile. The higher severe aGVHD warrants further study to optimize this regimen. The trial was registered at www.clinicaltrials.gov as #NCT01951885.
引用
- Hamilton BK, Rybicki LA, Li H, et al. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention. Blood Adv. 2023. PMID: 37352262. doi:10.1182/bloodadvances.2023010310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。